GLP-1

GLP-1 stands for Glucagon-like Peptide-1 — a messenger substance that the gut releases into the blood after a meal. Messenger substances of this kind are called hormones; they carry signals from one organ to another. GLP-1 tells the pancreas to release more insulin, and it signals the brain: “You’re full.” However, the body breaks down the hormone quickly, so the effect fades after just a few minutes. Medications that mimic GLP-1 while working far longer have fundamentally changed the treatment of diabetes and obesity in recent years.

GLP-1 as a turning point in diabetes therapy

Type 2 diabetes is a condition in which the body no longer reliably regulates its blood sugar. Too much sugar in the blood damages nerves, kidneys, and blood vessels over time. GLP-1 medications intervene exactly where the problem originates: they boost insulin production without lowering blood sugar so far that it becomes dangerously low. This makes them safer than older active substances.

On top of that comes an unexpected side effect: people taking GLP-1 medications eat less and often lose significant weight. Clinical trials — that is, tests with real patients under strictly controlled conditions — showed weight losses of up to 15 to 20 percent of body weight. That is more than any previous obesity medication has achieved. This propelled GLP-1 far beyond diabetes research into the center of medicine.

How GLP-1 medications replace the natural messenger substance

The problem with the body’s own GLP-1 is its short lifespan: an enzyme called DPP-4 breaks it down within two to three minutes. Pharmaceutical companies have therefore developed molecules that act just like GLP-1 but are resistant to this breakdown. They bind to the same docking sites — so-called receptors — on cells, but trigger a much longer-lasting effect. Depending on the active substance, a single weekly injection is enough.

The best-known active substances are called semaglutide and liraglutide. Semaglutide was originally developed for diabetes but is now also approved for obesity without diabetes. Newer medications combine GLP-1 with a second hormone — GIP — further amplifying the effect. This approach is called dual agonist therapy and is considered the next stage of development.

A common misconception: GLP-1 medications are not appetite suppressants in the classic sense. They don’t deceive the brain into a false state, but rather amplify a signal that arises naturally after eating — just longer and stronger. This explains why many users report that they simply feel satisfied sooner, not that they are permanently hungry.

GLP-1 in news, stock market reports, and everyday conversations

Anyone reading business or health news now encounters GLP-1 regularly. The manufacturer of the semaglutide drug Ozempic — the Danish company Novo Nordisk — temporarily became the most valuable company in Europe, driven solely by demand for GLP-1 medications. At the same time, analysts warn of supply shortages, as production capacities fail to keep pace with the boom.

GLP-1 medications are also sparking societal debates. Health insurers are arguing over whether obesity counts as a disease and whether the expensive drugs should be reimbursed. Personal accounts circulate on social media, but so does misinformation — for instance, the claim that the drugs are also useful for healthy people without any indication. Physicians warn that if the medication is stopped without a change in lifestyle, the weight usually comes back.

Beyond that, intensive research is underway into further areas of application: heart protection, kidney disease, and even possible effects on addictive behavior and dementia are being studied. GLP-1 has thus grown from a niche topic in endocrinology — the study of hormones — into one of the most widely discussed terms in medicine and finance.